LUCD · Lucid Diagnostics Inc. Common Stock
View on chartInsiders & Stakes
| PAVmed Inc. 10% Owner | ▼ Sell | Other | 31,302,444 Shares held | 2/15/2024 | View profile |
| Lishan Aklog Chairman and CEO | ▲ Buy | Grant | 3,636,627 Shares held | 2/20/2026 | View profile |
| Dennis M. McGrath Director | ▲ Buy | Grant | 1,813,569 Shares held | 2/20/2026 | View profile |
| Shaun O'Neil Chief Operating Officer | ▲ Buy | Grant | 1,446,763 Shares held | 2/20/2026 | View profile |
| Dennis Matheis Director | ▲ Buy | Open Market | 1,033,443 Shares held | 5/20/2026 | View profile |
| Michael Adam Gordon General Counsel | ▲ Buy | Grant | 1,000,000 Shares held | 2/20/2026 | View profile |
| James L. Cox Director | ▲ Buy | Grant | 405,120 Shares held | 2/20/2026 | View profile |
| John R. Palumbo Director | ▲ Buy | Grant | 338,000 Shares held | 2/20/2026 | View profile |
| Stanley Lapidus Director | ▲ Buy | Grant | 337,392 Shares held | 2/20/2026 | View profile |
| Ronald M. Sparks Director | ▲ Buy | Grant | 320,460 Shares held | 2/20/2026 | View profile |
| Jacque J. Sokolov Director | ▲ Buy | Grant | 320,460 Shares held | 2/20/2026 | View profile |
| Debra White Director | ▲ Buy | Grant | 235,800 Shares held | 2/20/2026 | View profile |
Transaction History
| Dennis Matheis | ▲ Buy | Open Market | 245,000 | $245K | 5/20/2026 |
| Dennis Matheis | ▲ Buy | Grant | 123,000 | $0 | 2/20/2026 |
| John R. Palumbo | ▲ Buy | Grant | 123,000 | $0 | 2/20/2026 |
| Stanley Lapidus | ▲ Buy | Grant | 123,000 | $0 | 2/20/2026 |
| James L. Cox | ▲ Buy | Grant | 123,000 | $0 | 2/20/2026 |
| Dennis M. McGrath | ▲ Buy | Grant | 470,000 | $0 | 2/20/2026 |
| Shaun O'Neil | ▲ Buy | Grant | 620,000 | $0 | 2/20/2026 |
| Michael Adam Gordon | ▲ Buy | Grant | 300,000 | $0 | 2/20/2026 |
| Lishan Aklog | ▲ Buy | Grant | 2,170,000 | $0 | 2/20/2026 |
| Debra White | ▲ Buy | Grant | 123,000 | $0 | 2/20/2026 |
| Ronald M. Sparks | ▲ Buy | Grant | 123,000 | $0 | 2/20/2026 |
| Jacque J. Sokolov | ▲ Buy | Grant | 123,000 | $0 | 2/20/2026 |
| Dennis Matheis | ▲ Buy | Open Market | 100,000 | $102K | 8/20/2025 |
| Dennis Matheis | ▲ Buy | Open Market | 33,218 | $44K | 5/22/2025 |
| Dennis Matheis | ▲ Buy | Open Market | 129,684 | $172K | 5/21/2025 |
| Dennis Matheis | ▲ Buy | Open Market | 187,098 | $242K | 5/20/2025 |
| Shaun O'Neil | ▲ Buy | Grant | 300,000 | $0 | 2/20/2025 |
| Lishan Aklog | ▲ Buy | Grant | 300,000 | $0 | 2/20/2025 |
| Jacque J. Sokolov | ▲ Buy | Grant | 112,800 | $0 | 2/20/2025 |
| Stanley Lapidus | ▲ Buy | Grant | 112,800 | $0 | 2/20/2025 |
| Dennis Matheis | ▲ Buy | Grant | 112,800 | $0 | 2/20/2025 |
| James L. Cox | ▲ Buy | Grant | 112,800 | $0 | 2/20/2025 |
| Dennis M. McGrath | ▲ Buy | Grant | 300,000 | $0 | 2/20/2025 |
| Michael Adam Gordon | ▲ Buy | Grant | 300,000 | $0 | 2/20/2025 |
| Debra White | ▲ Buy | Grant | 112,800 | $0 | 2/20/2025 |
| Ronald M. Sparks | ▲ Buy | Grant | 112,800 | $0 | 2/20/2025 |
| Michael Adam Gordon | ▲ Buy | Grant | 400,000 | $0 | 5/7/2024 |
| Shaun O'Neil | ▲ Buy | Grant | 400,000 | $0 | 5/7/2024 |
| Dennis M. McGrath | ▲ Buy | Grant | 400,000 | $0 | 5/7/2024 |
| Lishan Aklog | ▲ Buy | Grant | 400,000 | $0 | 5/7/2024 |
| PAVmed Inc. | ▼ Sell | Other | 3,331,747 | — | 2/15/2024 |
| PAVmed Inc. | ▼ Sell | Other | 3,331,771 | $4.7M | 1/26/2024 |
| Stanley Lapidus | ▼ Sell | Open Market | 10,000 | $15K | 9/26/2023 |
| Stanley Lapidus | ▼ Sell | Open Market | 10,000 | $14K | 9/26/2023 |
| Stanley Lapidus | ▼ Sell | Open Market | 9,747 | $14K | 9/26/2023 |
| Stanley Lapidus | ▼ Sell | Open Market | 200 | $286 | 9/25/2023 |
| Stanley Lapidus | ▼ Sell | Open Market | 100 | $144 | 9/21/2023 |
| Stanley Lapidus | ▼ Sell | Open Market | 3,405 | $5K | 9/20/2023 |
| Stanley Lapidus | ▼ Sell | Open Market | 412 | $593 | 9/20/2023 |
| Stanley Lapidus | ▼ Sell | Open Market | 17,000 | $29K | 9/20/2022 |
| Stanley Lapidus | ▼ Sell | Open Market | 16,864 | $29K | 9/20/2022 |
| Lishan Aklog | ▲ Buy | Grant | 60,000 | $0 | 1/7/2022 |
| Dennis M. McGrath | ▲ Buy | Grant | 60,000 | $0 | 1/7/2022 |
| PAVmed Inc. | ▲ Buy | Open Market | 571,428 | $8.0M | 10/18/2021 |
| Ronald M. Sparks | ▲ Buy | Grant | 84,660 | $0 | 10/18/2021 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Lucid Diagnostics Expands Payment Pathways for EsoGuard and EsoCheck
Lucid Diagnostics announced it has advanced several payment, billing, and coding pathways for its EsoGuard® and EsoCheck® products. This development could streamline reimbursement for the company’s diagnostic tests, potentially improving cash flow and market acceptance. The update follows the firm’s recent efforts to broaden its product ecosystem. Analysts maintain a target of $4.00, while the stock trades near its 52‑week low.
Lucid Diagnostics Expands Payment Pathways for EsoGuard and EsoCheck. Lucid Diagnostics announced it has advanced several payment, billing, and coding pathways for its EsoGuard® and EsoCheck® products. This development could streamline reimbursement for the company’s diagnostic tests, potentially improving cash flow and market acceptance. The update follows the firm’s recent efforts to broaden its product ecosystem. Analysts maintain a target of $4.00, while the stock trades near its 52‑week low.